Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and/or to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D.


  • Letter of Intent Due Date(s): May 22, 2021

  • Application Due Date(s): June 22, 2021

RFA-DK-21-005 Expiration Date June 23, 2021

Agency Website



Amount Description

Application budgets are limited to $600,000 direct costs per year. The budget needs to reflect the scientific scope of the proposed project.

The maximum project period is 5 years.

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Basic Science

External Deadline

June 22, 2021